Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

Jul 9, 2037patentUS 9968659*PED
Jul 9, 2037patentUS 9968659*PED
Jan 9, 2037method-of-use (U-2438)US 9968659
Jan 9, 2037method-of-use (U-2313)US 9968659
Feb 13, 2026patentUS 8114833*PED
Feb 13, 2026patentUS 8114833*PED
Aug 13, 2025compositionUS 8114833
Aug 13, 2025formulationUS 8114833

FDA exclusivities (1)

Feb 24, 2026PCPC

News(5)

Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
The additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major…
biospace · 10d ago
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
fiercebiotech · 10d ago
Compounders maintain a firm grip on the GLP-1 market
Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.
biopharma_dive · 28d ago
STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns
France's medicines regulator has fined Novo Nordisk and Eli Lilly over their weight loss ad campaigns.
stat · 3mo ago
STAT+: FDA wants to exclude weight loss drugs from a compounding list
FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.
stat · 3mo ago

brand

Saxenda

generic

liraglutide

MOA

12.1 Mechanism of Action Liraglutide is an acylated human Glucagon-Like Peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). GLP-1(7-37) represents <20% of total circulating endogenous GLP-1. Like GLP-1(7-37), liraglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase by the stimulatory G-protein, Gs, in pancreatic beta cells. Liraglutide increases intracellular cyclic AMP (cAMP) leading to insulin release in the presence of elevated glucose concentrations. This insulin secretion subsides as blood glucose concentrations decrease and approach euglycemia. Liraglutide also decreases glucagon secretion in a glucose-dependent manner. The mechanism of blood glucose lowering also involves a delay in gastric emptying. GLP-1(7-37) has a half-life of 1.5-2 minutes due to degradation by the ubiquitous endogenous enzymes, dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidases (NEP). Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-life of 13 hours after subcutaneous administration. The pharmacokinetic profile of liraglutide, which makes it suitable for once daily administration, is a result of self-association that delays absorption, plasma protein binding and stability against metabolic degradation by DPP-IV and NEP.

indication

Obesity

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 32m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

Saxenda

🐶 often sniffed alongside

indications

all catalysts(32)

Trials studying Saxenda

Patent cliff

patents (8)

FDA exclusivities (1)

News(5)

Report a data issue

comments(0)

Saxenda

🐶 often sniffed alongside

indications

all catalysts(32)

Trials studying Saxenda

Patent cliff

patents (8)

FDA exclusivities (1)

News(5)

Report a data issue

comments(0)